If NVG-300 works for Alzheimer's in NervGen's 2025 trial as well as their NVG-291 promises to work for spinal cord injury, it could be the most effective treatment.
@BioLabCollective Blarcamesine may be rejected by regulatory agencies not because it doesn't work but because it is produced by a small company and has really only bashers writing hit pieces among the pharmaceuticals media. Will post some more balanced articles here in the comments later.
If NVG-300 works for Alzheimer's in NervGen's 2025 trial as well as their NVG-291 promises to work for spinal cord injury, it could be the most effective treatment.
Need to watch this space for sure
Comment on Blarcamesine?
Will research this for a future episode!
@BioLabCollective Blarcamesine may be rejected by regulatory agencies not because it doesn't work but because it is produced by a small company and has really only bashers writing hit pieces among the pharmaceuticals media. Will post some more balanced articles here in the comments later.